Trump’s Executive Order On Drug Pricing Witnesses Litigation Challenges: Nirmal Bang
Tablets are arranged for a photograph. (Photographer: Kiyoshi Ota/Bloomberg)

Trump’s Executive Order On Drug Pricing Witnesses Litigation Challenges: Nirmal Bang

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Nirmal Bang Report

As a follow up to the Executive Order issued by U.S. President Donald Trump (September 13, 2020), the Center for Medicare and Medicaid Services was supposed to roll out a new payment model -- Most-favored-nation model -- to be effective from January 1, 2021.

However, the same has seen a litigation challenge and the District court in Maryland has recently issued an injunction on its implementation.

Click on the attachment to read the full report:

Nirmal Bang Pharmaceutical Sector- Sector Update -30 December 2020.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.